PARTNER BASE
Discover how LCC’s strategic partnerships drive innovation in drug discovery and explore opportunities to collaborate with us.
LCC’s partnership with Veritas in Silico.
The strategic partnership of VIS and LCC has united best-in-class biology
to develop small molecule assets against mRNA targets across oncology and rare diseases.
VIS has validated its biology platform for over 8 years via successful delivery for its clients.
VIS identifies the biological target
(i.e., the protein of interest that plays a key role in the disease).
LCC has built and validated its chemistry platform over 10 years via successful delivery across multiple target classes, including kinases, DUBs, and now mRNA small molecule targets.
LCC identifies tractable novel small molecule ligands that selectively bind to the biological target and elicit the desired therapeutic effect.
LCC (Chemistry) plus VIS (Biology) = JOINT ASSET DEVELOPMENT AND SALE
We are looking for partners with a validated, proprietary biology platform, able to work on structurally enabled targets.